Compositions and methods for the storage of red blood cells

Abstract

The present invention provides an aqueous composition for storage of red blood cells consisting essentially of: adenine; dextrose; at least one nonmetabolizable membrane-protectant sugar; and a specifically defined pH buffering system. Also provided are improved methods for preserving red blood cells and methods for increasing the viability, membrane retention, and recoverability while suppressing apoptosis, hemolysis, and post-reinfusion clearance of stored red blood cells which utilize the novel compositions.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional of and, pursuant to 35 U.S.C. §120, claims the benefit of U.S. patent application Ser. No. 11 / 060,026, filed on Feb. 17, 2005, which is pending as of the filing date of this application. Application Ser. No. 11 / 060,026, pursuant to 35 U.S.C. §119(e)(1), claimed priority from Provisional Application Ser. No. 60 / 545,582, filed on Feb. 18, 2004 under 35 U.S.C. §111(b). Both application Ser. No. 11 / 060,026 and Provisional Application Ser. No. 60 / 545,582 are hereby incorporated by reference in their entireties.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT[0002]Portions of this work were performed under U.S. Army contract DAMD 17-95-C-5029 and the U.S. government may have an ownership interest herein.BACKGROUND OF THE INVENTION[0003]The invention generally relates to compositions and methods associated with the storage of red blood cells (RBCs). In particular, it relates to an improved RBC stor...

AI Technical Summary

Benefits of technology

[0015]Accordingly, the present invention provides novel compositions suitable for the storage and preservation of collected red blood cells. The present inventors surprisingly discovered that substantially eliminating sodium chloride from such compositions, previously considered to be essential to proper operation of storage compositions, provides an increased capacity in the composition for an enhanced pH buffering system which, in turn, provides benefits both in terms of the integrity and physiological functioning quality of the stored and then re-infused red blood cells, and with respect to the length of time the RBCs may be stored with retention of the recoverability and hemolysis levels required under regulatory law for licensing. In addition, the inventive compositions retain their superior performance at conventional volumes, making them particularly suitable for storing red blood cells which may be targeted for infusion into multiply or massively transfused patients.

[0016]One embodiment of the present invention provides a composition for storage of red blood cells at about 1 to about 6° C. The composition consists essentially of: adenine; dextrose; at least one nonmetabolizable membrane-protectant sugar; and a pH buffering system. The pH buffering system comprises sodium bicarbonate and disodium phosphate and is present in an amount sufficient for the composition to have a pH of from about 8 to about 9. The composition is operable to maintain a pH of a red blood cell (RBC) suspension to which the composition is added at a value sufficient to establish and maintain during a storage period a reaction equilibrium in the red blood cell that favors glycolysis over synthesis of 2,3-diphosphoglycerate (DPG) from 1,3-DPG, thereby generating a net gain in adenosine tri phosphate (ATP) with respect to the reaction equilibrium during the storage period. Another embodiment of the invention provides that the composition is substantially free of sodium chloride.

[0020]Additional embodiments are provided which are directed to methods of using the inventive compositions to improve red blood cell (RBC) membrane maintenance and suppress RBC apoptosis during a storage period, to decrease red blood cell (REC) fragility and suppress RBC hemolysis during a storage period, and to increase viability of red blood cells (RBCs) subsequent to a storage period and after infusion into a patient in need of such an infusion, and decrease a rate of post-infusion clearance of the RBCs by the patient.

Problems solved by technology

Such preservation is scientifically tricky and the steps to achieving longer storage duration and higher quality re-infused red blood cells have been incremental.

This, however, led to a reduction in the percent recovery of the resulting “packed RBC.”

Red blood cells (RBCs) stored in these solutions, however, undergo steady deterioration after about 6 weeks as determined by the inability of 75% of such cells to survive in the circulation for 24 hours after re-infusion back into the human donor.

Each of the U.S.-licensed ASs meet the licensure requirements for 6-week RBC storage, but fail to achieve 7-week storage.

However, packed RBCs stored in EAS-2 were not directly infusible but required the removal of the supernatant with a washing step prior to transfusion due to the presence of ammonium in the additive solution.

However, the resulting RBC units contained about 1 percent glycerol and thus, are not safe for transfusion in humans in large amounts.

However, such stored RBC suspensions were not acceptable for direct infusion due to their high content of potassium and ammonia and their low volume fraction of RBCs.

Although these EASs yielded superior performance results, they contained sodium chloride and were formulated to require a relatively large volume resulting in greater dilution of the stored RBC, thus increasing the risk of hemodilution in multiply transfused patient recipients.

In addition, the presence of sodium chloride created a solubility limit on the amount of buffering salts and phosphates that the system could sustain at desirable volumes.

Images